NCT03904173View on ClinicalTrials.gov

Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

2,300

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2043

Conditions
Breast CancerBreast NeoplasmsHormone Receptor Positive Tumor
Interventions
DIAGNOSTIC_TEST

Multi-parameter tests

Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).

Trial Locations (5)

1714

Østfold Hospital, Sarpsborg

3004

Drammen Hospital - Vestre Viken, Drammen

3710

Telemark Hospital, Skien

5021

Haukeland University Hospital, Bergen

0424

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Klinbeforsk

OTHER

collaborator

Norwegian Cancer Society

OTHER

lead

Oslo University Hospital

OTHER

NCT03904173 - Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer | Biotech Hunter | Biotech Hunter